Mobile

Multi-center, open-label, multiple dose study in mild to moderate asthmatics (with IgE/body weight combinations above that in the SmPC dosing table) to determine safety, tolerability, pharmacokinetics...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005588-24

Multi-center, open-label, multiple dose study in mild to moderate asthmatics (with IgE/body weight combinations above that in the SmPC dosing table) to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of omalizumab

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate safety and tolerability of omalizumab in mild and moderate asthmatics with baseline IgE/body-weight combinations above those defined in the SmPC table.

Critère d'inclusion

  • Mild to moderate allergic asthma

Liens